Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05035706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started2021-06-30
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 24 months later Apr 30, 2026 → Apr 30, 2028
See other at-risk trials from M.D. Anderson Cancer Center

Amendment history

2026-09-23
Primary completion pushed: 2026-04-30 → 2028-04-30
Completion pushed: 2026-04-30 → 2028-04-30
2026-03-03
2 amendments v7-v8
2 re-verifications since 2025-09-04, no change to tracked fields
2025-03-31
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v6
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2024-10-17
Study Status v5
Re-verified, no change to tracked fields
2024-04-17
Study Status v4
Primary completion date2024-04-30→2026-04-30
Completion date2024-04-30→2026-04-30
2023-10-05
3 amendments v1-v3
3 re-verifications since 2021-09-09, no change to tracked fields
2021-08-30
Original filing
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that uses the immune system to fight cancer) can be helpful in future leukemia patients receiving radiation.
Trial Details
NCT Number NCT05035706
Lead Sponsor M.D. Anderson Cancer Center
Conditions Acute Myeloid Leukemia, Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Enrollment 10 participants
Start Date 2021-06-30
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-22